IMCY-0141
- Generic Name
- IMCY-0141
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin sheath protecting the nerves.
- Associated Conditions
- -
- Associated Therapies
- -
Multiple Sclerosis Drug Pipeline Research Report 2024
The 'Multiple Sclerosis - Pipeline Insight, 2024' report by ResearchAndMarkets.com covers 80+ companies and 85+ pipeline drugs, including IMU-838 (Immunic), Masitinib (AB Science), Foralumab (Tiziana Life Sciences), IMCY-0141 (ImCyse), and BMS-986353 (Bristol-Myers Squibb). It provides insights into clinical and nonclinical stage products, therapeutics assessment, and pipeline development activities.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath